1,3-Benzenedimethanamine, reaction products with glycidyl tolyl ether

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

This study was conducted between 19 July 2017 and 15 August 2017

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Reliability 1 is assigned because the study conducted according to OECD TG 420 in compliance with GLP, without deviations that influence the quality of the results.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2017

Report date:

2017

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)

Version / remarks:

2001

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)

Version / remarks:

EC NO. 440/2008

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

fixed dose procedure

Test material

Test material information

Constituent 1

Reference substance name:

2-​Propanol, 1-​[[[3-​(aminomethyl)​phenyl]​methyl]​amino]​-​3-​(2-​methylphenoxy)​-

Cas Number:

1617528-47-8

Molecular formula:

C18H24N2O2

IUPAC Name:

2-​Propanol, 1-​[[[3-​(aminomethyl)​phenyl]​methyl]​amino]​-​3-​(2-​methylphenoxy)​-

Constituent 2

Reference substance name:

3,3'-[benzene-1,3-diylbis(methanediylimino)]bis[1-(2-methylphenoxy)propan-2-ol]

Molecular formula:

C28H36N2O4

IUPAC Name:

3,3'-[benzene-1,3-diylbis(methanediylimino)]bis[1-(2-methylphenoxy)propan-2-ol]

Constituent 3

Reference substance name:

m-phenylenebis(methylamine)

EC Number:

216-032-5

EC Name:

m-phenylenebis(methylamine)

Cas Number:

1477-55-0

Molecular formula:

C8H12N2

IUPAC Name:

1,3-phenylenedimethanamine

impurity 1

Reference substance name:

2-Propanol, 1,3-bis(2-methylphenoxy)-

Cas Number:

17181-49-6

Molecular formula:

C17H20O3

IUPAC Name:

2-Propanol, 1,3-bis(2-methylphenoxy)-

impurity 2

Reference substance name:

1-{[2-hydroxy-3-(2-methylphenoxy)propyl][3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)benzyl]amino}-3-(2-methylphenoxy)propan-1-ol

Molecular formula:

C38H48N2O6

IUPAC Name:

1-{[2-hydroxy-3-(2-methylphenoxy)propyl][3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)benzyl]amino}-3-(2-methylphenoxy)propan-1-ol

impurity 3

Reference substance name:

3,3',3'',3'''-[benzene-1,3-diylbis(methanediylnitrilo)]tetrakis[1-(2-methylphenoxy)propan-2-ol]

Molecular formula:

C48H60N2O8

IUPAC Name:

3,3',3'',3'''-[benzene-1,3-diylbis(methanediylnitrilo)]tetrakis[1-(2-methylphenoxy)propan-2-ol]

Test material form:

liquid: viscous

Details on test material:

Identification:
1,3-Benzenedimethanamine, reaction products with glycidyl tolyl ether
Appearance/Physical state:
clear, colorless, viscous liquid
Batch:
WA 1508
Purity:
100% UVCB
Expiry date:
01 January 2021
Storage conditions:
room temperature, in the dark

Specific details on test material used for the study:

Identification: 1,3-Benzenedimethanamine, reaction products with glycidyl tolyl ether
Batch: WA 1508
Purity: not supplied
Physical state / Appearance: clear colorless viscous liquid
Expiry Date: 01 January 2021
Storage Conditions: room temperature in the dark

Test animals

Species:

rat

Strain:

Wistar

Remarks:

RccHan™:WIST

Sex:

female

Details on test animals or test system and environmental conditions:

Female Wistar (RccHan™:WIST) strain rats were supplied by Envigo RMS (UK) Limited, Oxon, UK. On receipt the animals were randomly allocated to cages. The females were nulliparous and non pregnant. After an acclimatization period of at least 5 days the animals were selected at random and given a number unique within the study by indelible ink marking on the tail and a number written on a cage card. At the start of the study the animals were 8 to 12 weeks of age. The body weight variation did not exceed ±20% of the mean body weight at the start of treatment.

Animal Care and Husbandry
The animals were housed in groups of up to four in suspended solid floor polypropylene cages furnished with woodflakes. With the exception of an overnight fast immediately before dosing and for approximately 3 to 4 hours after dosing, free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK) was allowed throughout the study. The diet, drinking water and bedding were routinely analyzed and were considered not to contain any contaminants that would reasonably be expected to affect the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25 °C and 30 to 70% respectively. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give 12 hours continuous light and 12 hours darkness.
The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

DMSO

Details on oral exposure:

Test Item Preparation and Analysis
For the purpose of the 2000 mg/kg dose level, the test item was used as supplied. The specific gravity was determined and used to calculate the appropriate dose volume for the required dose level. For the purpose of the 300 mg/kg dose level, the test item was freshly prepared, as required, as a solution in dimethyl sulfoxide. Dimethyl sulfoxide was used because the test item did not dissolve/suspend in distilled water or arachis oil BP.

The test item was formulated within 2 hours of being applied to the test system. It is assumed that the formulation was stable for this duration.
No analysis was conducted to determine the homogeneity, concentration or stability of the test item formulation. This is an exception with regard to GLP and has been reflected in the GLP compliance statement.

Doses:

300 and 2000 mg/kg

No. of animals per sex per dose:

1 rat - 2000 mg/kg
5 rats - 300 mg/kg

Control animals:

no

Details on study design:

Study Design
Using available information on the toxicity of the test item, 2000 mg/kg was chosen as the starting dose.
A single animal was treated as follows:
Dose Level(mg/kg) Specific Gravity Dose Volume(mL/kg) Number of Rats
2000 1.105 1.81 1

Due to mortality at a dose level of 2000 mg/kg, an additional animal was treated as follows:
Dose Level(mg/kg) Concentration(mg/mL) Dose Volume(mL/kg) Number of Rats
300 30 10 1

In the absence of toxicity at a dose level of 300 mg/kg, an additional group of animals was treated as follows:
Dose Level(mg/kg) Concentration (mg/mL) Dose Volume (mL/kg) Number of Rats
300 30 10 4

A total of five animals were therefore treated at a dose level of 300 mg/kg in the study.
All animals were dosed once only by gavage, using a metal cannula attached to a graduated syringe. The volume administered to each animal was calculated according to the fasted body weight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each dose group to confirm the survival of the previously dosed animals.
Clinical observations were made 30 minutes, 1, 2, and 4 hours after dosing and then daily for up to 14 days. Morbidity and mortality checks were made twice daily, early and late during normal working days, and once daily at weekends and public holidays.
Individual body weights were recorded on Day 0 (the day of dosing) and on Days 7 and 14 or at death.
At the end of the observation period the surviving animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.

Data Evaluation
The test item was classified according to Annex 3 of the OECD Guidelines for Testing of Chemicals No. 420 "Acute Oral Toxicity - Fixed Dose Procedure" (adopted 17 December 2001).
Evaluation of data included identification of the number of animals that died during the study (or that were killed for humane reasons), and determination of the nature, severity, onset and duration of the toxic effects. If possible, the signs of evident toxicity were described. Evident toxicity refers to the toxic effects of sufficient severity that administration of the next higher dose level could result in development of severe signs of toxicity and probable mortality. Effects on body weights and abnormalities noted at necropsy were also identified.
Using the mortality data obtained, an estimate of the acute oral median lethal dose (LD50) of the test item was made.

Results and discussion

Effect levels

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 300 - < 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: Globally Harmonized Classification System - Category 4

Mortality:

Dose Level - 2000 mg/kg
Mortality
The animal was found dead 1 day after dosing

Dose Level - 300 mg/kg
There were no deaths.

Clinical signs:

other: Dose Level - 2000 mg/kg Hunched posture and ataxia were noted during the day of dosing. Dose Level - 300 mg/kg No signs of systemic toxicity were noted during the observation period.

Gross pathology:

Dose Level - 2000 mg/kg
Abnormalities noted at necropsy were dark liver, dark kidneys, hemorrhagic gastric mucosa and hemorrhagic non glandular epithelium of the stomach

Dose Level - 300 mg/kg
No abnormalities were noted at necropsy.

Other findings:

No other findings noted

Applicant's summary and conclusion

Interpretation of results:

Category 4 based on GHS criteria

Conclusions:

The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be in the range of 300 to 2000 mg/kg body weight (Globally Harmonized Classification System - Category 4).

Executive summary:

The study was performed to assess the acute oral toxicity of the test item in the Wistar strain rat.

Methods

Following a sighting test at dose levels of2000 mg/kg and300 mg/kg, a further group of four fasted females was given a single oral dose of test item, as asolutionindimethyl sulfoxide, at a dose level of300 mg/kg body weight. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.

Results

Mortality. The animal treated at a dose level of 2000 mg/kg was found dead 1 day after dosing. There were no deaths noted at a dose level of 300 mg/kg.

Clinical Observations. Hunched posture and ataxia were noted in the animal treated at a dose level of 2000 mg/kg. There were no signs of systemic toxicity noted at a dose level of 300 mg/kg.

Body Weight. Surviving animals showed expected gains in body weight.

Necropsy. Abnormalities noted at necropsy of the animal treated at a dose level of 2000 mg/kg that died during the study were dark liver, dark kidneys, hemorrhagic gastric mucosa and hemorrhagic non‑glandular epithelium of the stomach. No abnormalities were noted at necropsy of animals treated at a dose level of 300 mg/kg.

Conclusion

The acute oral median lethal dose (LD₅₀) of the test item in the female Wistar strain rat was estimated to be in the range of300 ‑ 2000 mg/kg body weight (Globally Harmonized Classification System-Category 4).